Thomas Jefferson University
Kevin Lam, PharmD, is a T32 Clinical Pharmacology Postdoctoral Fellow at Thomas Jefferson University. He graduated with his PharmD from St. John's University College of Pharmacy and Health Sciences (Queens, NY) in May 2022. He has recently presented the results of a drug-drug interaction study involving doravirine, lamivudine, tenofovir disoproxil fumarate, and feminizing hormone therapy in transgender women at IDWeek 2023, which was later accepted to Clinical and Translational Sciences. His research interests include PKPD modeling, drug-drug interactions, obstetric pharmacology, and neonatal opioid withdrawal syndrome.